eligibility_summary
Inclusion: age 18–75, ECOG 0–1, life expectancy >3 mo, advanced solid tumor recurrent/metastatic after ≥2 lines, CD70+ by IHC, measurable disease, adequate organ function, negative pregnancy test/contraception, consent. Exclusion: recent cell/immuno/targeted/chemo, other malignancy ≤2 yrs (except cured in situ/skin/bladder), CNS/leptomeningeal mets, HBV/HIV/HCV, active infection, major cardiac/respiratory disease, uncontrolled effusions, autoimmune disease, steroid use, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06728189 (Phase 1). Intervention: CGC738, a CD70-targeted CAR-NKT cell therapy (genetically engineered autologous natural killer T cells expressing an anti-CD70 chimeric antigen receptor). Mechanism: CAR binding to CD70 on tumor cells triggers NKT-cell cytotoxicity (perforin/granzyme) and cytokine release, enhancing anti-tumor immunity independent of native TCR, aims to eliminate CD70+ solid tumors and disrupt the CD70–CD27 axis often upregulated in cancers. Conditioning: lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog) to reduce host lymphocytes and support CAR-NKT expansion. Doses: 5.0×10^6, 1.5×10^7, or 4.5×10^7 CAR-NKT cells/m^2. Targets: CD70-expressing tumor cells, immune pathways include CAR signaling in NKT cells and preconditioning-induced lymphodepletion.